- The two presentations at AMP highlight the role of next-generation sequencing in lung cancer biomarker testing, including CGI’s liquid biopsy test, Liquid::Lung-cfDNA™
- Thermo Fisher’s next-generation sequencing panels are utilized by CGI as novel testing approaches to advance lung cancer precision medicine and eliminate time-consuming screening
RUTHERFORD, N.J., Nov. 08, 2017 (GLOBE NEWSWIRE) — Cancer Genetics, Inc. (Nasdaq:CGIX), a leader in enabling precision medicine for oncology through molecular markers and diagnostics, today announced that it will deliver two presentations on non-small cell lung cancer (NSCLC) at a workshop hosted by Thermo Fisher Scientific during the Association for Molecular Pathology (AMP) Annual Meeting, taking place November 16-18, 2017 in Salt Lake City, Utah. In addition, CGI will be exhibiting its wide range of products and services at the conference at CGI Booth #908.
Both oral presentations will take place during Thermo Fisher’s workshop titled “Next generation sequencing (NGS) in NSCLC biomarker testing” at 8:00 am MST on November 15th:
Oral Presentation Title: Cell-free DNA and Lung Cancer Clinical Research
Session: Clinical Research Testing
Presenter: CGI’s Associate Director of Molecular Diagnostics Charles Ma, PhD
Synopsis: The presentation will cover how lung cancer liquid biopsy next-generation sequencing (NGS) testing can change the paradigm for lung cancer monitoring. Dr. Ma will present case studies demonstrating changes in the course of therapy leading to improved outcomes based on CGI’s Liquid::Lung-cfDNA™ test. The test is based on Thermo Fisher’s Oncomine™ Lung cfDNA assay and is available at CGI for both clinical care and for trials being performed by biotech and pharmaceutical companies.
Oral Presentation Title: More with Less, Clinical Next Generation Sequencing
Session: Companion Diagnostics Testing
Presenter: CGI’s Medical Director Daniel Duncan, MD
Synopsis: The presentation will discuss how NGS can simplify the current elaborate testing algorithms of NSCLC and consolidate workflow. The talk will also explain how Thermo Fisher’s newly FDA-approved, multi-biomarker Oncomine Dx Target Test, which CGI now offers, is effective at delivering clinically-relevant information for NSCLC patients with minimum tissue requirements, streamlining how NSCLC patients are screened for FDA-approved targeted therapies. CGI is one of the first laboratories and precision medicine companies globally to make the novel, 23-gene Oncomine Dx Target Test available to the medical community.
CGI has an extensive heritage in biomarker and molecular profiling for lung cancer, and is very pleased to be able to continuously add novel lung cancer tests to its comprehensive menu of cutting-edge diagnostic services, as well as be one of the leading labs in the nation to provide rapid access to such tests. To learn more about CGI’s offerings for NCSLC, please refer to Lung Complete™ – a unique suite of common and proprietary tests integrating the latest diagnostic, prognostic, and predictive markers to assist in lung cancer management.
ABOUT CANCER GENETICS
Cancer Genetics Inc. is a leader in enabling precision medicine in oncology from bench to bedside through the use of oncology biomarkers and molecular testing. CGI is developing a global footprint with locations in the US, India and China. We have established strong clinical research collaborations with major cancer centers such as Memorial Sloan Kettering, The Cleveland Clinic, Mayo Clinic, Keck School of Medicine at USC and the National Cancer Institute.
The Company offers a comprehensive range of laboratory services that provide critical genomic and biomarker information. Its state-of-the-art reference labs are CLIA-certified and CAP-accredited in the US and have licensure from several states including New York State.
For more information, please visit or follow CGI at:
Internet: www.cancergenetics.com
Twitter: @Cancer_Genetics
Facebook: www.facebook.com/CancerGenetics
Forward-Looking Statements:
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements pertaining to Cancer Genetics Inc.’s expectations regarding the completion, timing, pricing and size of the offering described in this press release constitute forward-looking statements.
Any statements that are not historical fact (including, but not limited to, statements that contain words such as “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates”) should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, risks of cancellation of customer contracts or discontinuance of trials, risks that anticipated benefits from acquisitions will not be realized, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, maintenance of intellectual property rights and other risks discussed in the Cancer Genetics, Inc. Form 10-K for the year ended December 31, 2016 and the Form 10-Q for the Quarter ended June 30, 2017 along with other filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Cancer Genetics, Inc. disclaims any obligation to update these forward-looking statements.
Contacts
Media Relations
Kirsten Thomas
508-280-6592
kthomas@theruthgroup.com
Investor Relations
Lee Roth / Robert Flamm
646-536-7012 / 7017
lroth@theruthgroup.com / rflamm@theruthgroup.com
